Nicolas Ortonne1, Pierre Wolkenstein2, Jaishri O Blakeley1, Bruce Korf1, Scott R Plotkin1, Vincent M Riccardi1, Douglas C Miller1, Susan Huson1, Juha Peltonen1, Andrew Rosenberg1, Steven L Carroll1, Sharad K Verma1, Victor Mautner1, Meena Upadhyaya1, Anat Stemmer-Rachamimov1. 1. From the Departments of Pathology (N.O.) and Dermatology (P.W.), French Referral Center for Neurofibromatoses, Henri-Mondor Hospital, AP-HP, University Paris Est Créteil, France; Department of Neurology (J.O.B., S.K.V.), Johns Hopkins University School of Medicine, The Neurofibromatosis Therapuetic Acceleration Program, Baltimore, MD; University of Alabama at Birmingham (B.K.); Cancer Center and Department of Neurology (S.R.P.) and Department of Pathology, Division of Neuropathology (A.S.-R.), Massachusetts General Hospital, Boston; The Neurofibromatosis Institute (V.M.R.), La Crescenta, CA; Department of Pathology & Anatomical Sciences (D.C.M.), University of Missouri School of Medicine, Columbia; Manchester Centre for Genomic Medicine (S.H.), Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, UK; Institute of Biomedicine (J.P.), University of Turku, Finland; Department of Pathology and Laboratory Medicine (A.R.), Jackson Memorial Hospital/University of Miami Miller School of Medicine, FL; Department of Pathology and Laboratory Medicine (S.L.C.), Medical University of South Carolina, Charleston; Clinics and Polyclinics of Neurology (V.M.), University Hospital Hamburg-Eppendorf, Hamburg, Germany; and Division of Cancer and Genetics (M.U.), Institute of Medical Genetics, Cardiff University, UK. 2. From the Departments of Pathology (N.O.) and Dermatology (P.W.), French Referral Center for Neurofibromatoses, Henri-Mondor Hospital, AP-HP, University Paris Est Créteil, France; Department of Neurology (J.O.B., S.K.V.), Johns Hopkins University School of Medicine, The Neurofibromatosis Therapuetic Acceleration Program, Baltimore, MD; University of Alabama at Birmingham (B.K.); Cancer Center and Department of Neurology (S.R.P.) and Department of Pathology, Division of Neuropathology (A.S.-R.), Massachusetts General Hospital, Boston; The Neurofibromatosis Institute (V.M.R.), La Crescenta, CA; Department of Pathology & Anatomical Sciences (D.C.M.), University of Missouri School of Medicine, Columbia; Manchester Centre for Genomic Medicine (S.H.), Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, UK; Institute of Biomedicine (J.P.), University of Turku, Finland; Department of Pathology and Laboratory Medicine (A.R.), Jackson Memorial Hospital/University of Miami Miller School of Medicine, FL; Department of Pathology and Laboratory Medicine (S.L.C.), Medical University of South Carolina, Charleston; Clinics and Polyclinics of Neurology (V.M.), University Hospital Hamburg-Eppendorf, Hamburg, Germany; and Division of Cancer and Genetics (M.U.), Institute of Medical Genetics, Cardiff University, UK. pierre.wolkenstein@aphp.fr.
Abstract
OBJECTIVE: To present the current terminology and natural history of neurofibromatosis 1 (NF1) cutaneous neurofibromas (cNF). METHODS: NF1 experts from various research and clinical backgrounds reviewed the terms currently in use for cNF as well as the clinical, histologic, and radiographic features of these tumors using published and unpublished data. RESULTS: Neurofibromas develop within nerves, soft tissue, and skin. The primary distinction between cNF and other neurofibromas is that cNF are limited to the skin whereas other neurofibromas may involve the skin, but are not limited to the skin. There are important cellular, molecular, histologic, and clinical features of cNF. Each of these factors is discussed in consideration of a clinicopathologic framework for cNF. CONCLUSION: The development of effective therapies for cNF requires formulation of diagnostic criteria that encompass the clinical and histologic features of these tumors. However, there are several areas of overlap between cNF and other neurofibromas that make distinctions between cutaneous and other neurofibromas more difficult, requiring careful deliberation with input across the multiple disciplines that encounter these tumors and ultimately, prospective validation. The ultimate goal of this work is to facilitate accurate diagnosis and meaningful therapeutics for cNF.
OBJECTIVE: To present the current terminology and natural history of neurofibromatosis 1 (NF1) cutaneous neurofibromas (cNF). METHODS: NF1 experts from various research and clinical backgrounds reviewed the terms currently in use for cNF as well as the clinical, histologic, and radiographic features of these tumors using published and unpublished data. RESULTS: Neurofibromas develop within nerves, soft tissue, and skin. The primary distinction between cNF and other neurofibromas is that cNF are limited to the skin whereas other neurofibromas may involve the skin, but are not limited to the skin. There are important cellular, molecular, histologic, and clinical features of cNF. Each of these factors is discussed in consideration of a clinicopathologic framework for cNF. CONCLUSION: The development of effective therapies for cNF requires formulation of diagnostic criteria that encompass the clinical and histologic features of these tumors. However, there are several areas of overlap between cNF and other neurofibromas that make distinctions between cutaneous and other neurofibromas more difficult, requiring careful deliberation with input across the multiple disciplines that encounter these tumors and ultimately, prospective validation. The ultimate goal of this work is to facilitate accurate diagnosis and meaningful therapeutics for cNF.
Authors: George-Sorin Tiplica; Klaus Fritz; Alexandra Irina Butacu; Loredana Ungureanu; Carmen Maria Sălăvăstru Journal: Hautarzt Date: 2022-01-25 Impact factor: 0.751
Authors: Isis Atallah; Ana M Cieza Rivera; Octavio M Rivero Lezcano; Laura Tascón-González; Carolina González-Cortés; Cristina Diez Tascón; Tania Fernández-Villa; Vicente Martín Journal: Am J Transl Res Date: 2022-05-15 Impact factor: 3.940
Authors: Nicolas Ortonne; Steven L Carroll; Fausto J Rodriguez; Douglas C Miller; Rosalynn M Nazarian; Jaishri O Blakeley; Zachary B Madaj; Sharad K Verma; Anat Stemmer-Rachamimov Journal: Neurooncol Adv Date: 2019-12-05
Authors: Fausto J Rodriguez; Mindy K Graham; Jacqueline A Brosnan-Cashman; John R Barber; Christine Davis; M Adelita Vizcaino; Doreen N Palsgrove; Caterina Giannini; Melike Pekmezci; Sonika Dahiya; Murat Gokden; Michael Noë; Laura D Wood; Christine A Pratilas; Carol D Morris; Allan Belzberg; Jaishri Blakeley; Christopher M Heaphy Journal: Acta Neuropathol Commun Date: 2019-08-28 Impact factor: 7.578
Authors: Jamie L Grit; Benjamin K Johnson; Patrick S Dischinger; Curt J Essenburg; Marie Adams; Stacy Campbell; Kai Pollard; Christine A Pratilas; Tim J Triche; Carrie R Graveel; Matthew R Steensma Journal: Epigenetics Chromatin Date: 2021-01-13 Impact factor: 4.954
Authors: Juan Mo; Corina Anastasaki; Zhiguo Chen; Tracey Shipman; Jason Papke; Kevin Yin; David H Gutmann; Lu Q Le Journal: J Clin Invest Date: 2021-01-04 Impact factor: 14.808